Nintedanib

Nintedanib is a prescription medication that belongs to a class of drugs called tyrosine kinase inhibitors. It is specifically an inhibitor of the receptor tyrosine kinases, which are involved in the growth and spread of cancer cells. Nintedanib is primarily used to treat idiopathic pulmonary fibrosis, a chronic lung disease characterized by scarring and thickening of lung tissues.
In idiopathic pulmonary fibrosis, nintedanib works by inhibiting multiple signaling pathways that promote the growth and survival of fibroblasts, the cells responsible for producing the excessive collagen and other extracellular matrix proteins that cause lung scarring. By targeting these pathways, nintedanib reduces the rate of lung function decline and improves symptoms in patients with this debilitating condition.
In addition to its use in idiopathic pulmonary fibrosis, nintedanib has also shown promise in the treatment of other lung diseases, such as systemic sclerosis-associated interstitial lung disease and chronic obstructive pulmonary disease. However, consult with a healthcare professional before starting any new medication to ensure that it is appropriate for the specific condition being treated.
Nintedanib is available in tablet form and is typically taken twice daily, with or without food. The most common side effects associated with nintedanib include diarrhea, nausea, and increased liver enzymes. As with any medication, discuss potential side effects and precautions with a healthcare professional before starting treatment.